Synonym
NVX-207; NVX207; NVX 207
IUPAC/Chemical Name
2-amino-3-hydroxy-2-(hydroxymethyl)propyl (1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-9-acetoxy-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)icosahydro-3aH-cyclopenta[a]chrysene-3a-carboxylate
InChi Key
KQZVSTAVTJCKDG-DRSBITMPSA-N
InChi Code
InChI=1S/C36H59NO6/c1-22(2)24-11-16-36(30(41)42-21-35(37,19-38)20-39)18-17-33(7)25(29(24)36)9-10-27-32(6)14-13-28(43-23(3)40)31(4,5)26(32)12-15-34(27,33)8/h24-29,38-39H,1,9-21,37H2,2-8H3/t24-,25+,26-,27+,28-,29+,32-,33+,34+,36-/m0/s1
SMILES Code
O=C([C@]1(CC[C@H]2C(C)=C)[C@@]2([H])[C@@]3([H])CC[C@]4([H])[C@@]5(C)CC[C@H](OC(C)=O)C(C)(C)[C@]5([H])CC[C@@]4(C)[C@]3(C)CC1)OCC(CO)(N)CO
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
601.86
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Liebscher G, Vanchangiri K, Mueller T, Feige K, Cavalleri JM, Paschke R. In vitro anticancer activity of Betulinic acid and derivatives thereof on equine melanoma cell lines from grey horses and in vivo safety assessment of the compound NVX-207 in two horses. Chem Biol Interact. 2016 Feb 25;246:20-9. doi: 10.1016/j.cbi.2016.01.002. PubMed PMID: 26772157.
2: Bache M, Bernhardt S, Passin S, Wichmann H, Hein A, Zschornak M, Kappler M, Taubert H, Paschke R, Vordermark D. Betulinic acid derivatives NVX-207 and B10 for treatment of glioblastoma--an in vitro study of cytotoxicity and radiosensitization. Int J Mol Sci. 2014 Oct 30;15(11):19777-90. doi: 10.3390/ijms151119777. PubMed PMID: 25361208; PubMed Central PMCID: PMC4264138.
3: Willmann M, Wacheck V, Buckley J, Nagy K, Thalhammer J, Paschke R, Triche T, Jansen B, Selzer E. Characterization of NVX-207, a novel betulinic acid-derived anti-cancer compound. Eur J Clin Invest. 2009 May;39(5):384-94. doi: 10.1111/j.1365-2362.2009.02105.x. PubMed PMID: 19309323.
